47 completed. 47 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 47 | Completed 47 |
| Phase 2 | 7 | Completed 7 |
Follow Hypertriglyceridemia: new trials by email Literature Review of Hypertriglyceridemia trials Research Report on Hypertriglyceridemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD) mibavademab - Generalized Lipodystrophy | Phase 3 | Completed | Regeneron Pharmaceuticals | 9 | 2024-12-16 | 2026-07-29 |
| Study of Plozasiran in Adults With Severe Hypertriglyceridemia Plozasiran Injection, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Arrowhead Pharmaceuticals | 311 | 2024-07-23 | 2026-10-09 |
| Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia Plozasiran Injection, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Arrowhead Pharmaceuticals | 446 | 2024-07-22 | 2026-10-08 |
| Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia Plozasiran Injection, Placebo - Hypertriglyceridemia | Phase 3 | Completed | Arrowhead Pharmaceuticals | 1456 | 2024-05-21 | 2026-09-25 |
| To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia Pegozafermin, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | 89bio, Inc. | 369 | 2023-06-15 | 2026-07-07 |
| A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia Olezarsen, Placebo - Hypertriglyceridemia, Cardiovascular Diseases | Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 1478 | 2022-11-21 | 2026-02-10 |
| A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Olezarsen, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 446 | 2022-08-31 | 2025-10-22 |
| A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia Olezarsen, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 617 | 2021-10-25 | 2026-02-10 |
| Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage SHR-1209, SHR-1209 Placebo - Primary Hypercholesterolemia, Mixed Hyperlipemia | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 709 | 2021-04-23 | 2023-05-19 |
| Efficacy and Safety of Cipros 10 Association on the Isolated Hypertriglyceridemia and Dyslipidemia Treatment Cipros 10 association, Crestor 10 mg - Hypertriglyceridemia, Dyslipidemia | Phase 3 | Completed | EMS | 146 | 2021-01-29 | 2025-12-08 |
| Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia Placebo, Ethyl Icosapentate - Hypertriglyceridemia | Phase 3 | Completed | Mochida Pharmaceutical Company, Ltd. | 316 | 2020-05-09 | 2024-07-15 |
| Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia Icosapent - Hypertriglyceridemia | Phase 3 | Completed | Mochida Pharmaceutical Company, Ltd. | 120 | 2020-02-14 | 2021-08-23 |
| Efficacy of MND-2119 in Participants With Hypertriglyceridemia Icosapent (MND-2119), Icosapent (EPADEL CAPSULES 300) - Hypertriglyceridemia | Phase 3 | Completed | Mochida Pharmaceutical Company, Ltd. | 580 | 2018-10-27 | 2019-08-01 |
| A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2) CaPre, Placebo - Hypertriglyceridemia | Phase 3 | Completed | Grace Therapeutics Inc. | 278 | 2018-02-01 | 2020-08-12 |
| A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1) CaPre, Placebo - Hypertriglyceridemia | Phase 3 | Completed | Grace Therapeutics Inc. | 256 | 2018-01-23 | 2020-01-18 |
| Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function K-877, Fenofibrate, Placebo (for K-877) - Severe Hypertriglyceridemia | Phase 3 | Completed | Kowa Research Institute, Inc. | 551 | 2016-11-28 | 2022-11-30 |
| Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment K-877, Fenofibrate, Placebo (for K-877) - Severe Hypertriglyceridemia | Phase 3 | Completed | Kowa Research Institute, Inc. | 471 | 2016-11-26 | 2022-10-28 |
| Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes Totum-63, Placebo - Prediabetes, Type 2 Diabetes | Phase 2 / Phase 3 | Completed | Valbiotis | 66 | 2016-10-01 | 2020-10-05 |
| An Efficacy and Safety Study of Omega-3-acid Ethyl Ester in Chinese Subjects With Hypertriglyceridemia. Omega-3-acid ethyl ester or Placebo - Hypertriglyceridemia | Phase 3 | Completed | Abbott | 248 | 2016-10-01 | 2021-03-05 |
| AZD0585 Phase III Long-term Study in Japan AZD0585, AZD0585 placebo - Hypertriglyceridemia | Phase 3 | Completed | AstraZeneca | 383 | 2015-06-10 | 2018-10-01 |
Showing 20 of 47. Sign in to see all of them.
Dyslipidemias (11) · Hyperlipidemias (10) · Hypercholesterolemia (5) · Cardiovascular Diseases (3) · Hyperlipoproteinemia Type II (3) · Insulin Resistance (3) · Diabetes Mellitus, Type 2 (2) · Hypertension (2) · Metabolic Diseases (2) · Metabolic Syndrome (2) · Obesity (2) · Acute Coronary Syndrome (1) · Angina Pectoris (1) · Arterial Occlusive Diseases (1)
Nutritional and Metabolic Diseases (47) · Lipid Metabolism Disorders (46) · Metabolic Diseases (45) · Hyperlipidemias (37) · Dyslipidemias (36) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (6) · Lipid Metabolism, Inborn Errors (6) · Metabolism, Inborn Errors (6) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Glucose Metabolism Disorders (5) · Hyperinsulinism (5) · Hyperlipoproteinemias (5) · Body Weight (3)
Omacor (7) · eicosapentaenoic acid ethyl ester (7) · Fenofibrate (3) · Olive Oil (3) · Simvastatin (3) · eicosapentaenoic acid ethanolamide (3) · olezarsen (3) · plozasiran (3) · Atorvastatin (2) · Corn Oil (2) · Eicosapentaenoic Acid (2) · Ezetimibe (2) · K-877 compound (2) · TAK-085 (2) · Ezetimibe, Simvastatin Drug Combination (1)
AstraZeneca (5) · Ionis Pharmaceuticals, Inc. (4) · Amarin Pharma Inc. (3) · Arrowhead Pharmaceuticals (3) · GlaxoSmithKline (3) · Mochida Pharmaceutical Company, Ltd. (3) · Organon and Co (3) · Grace Therapeutics Inc. (2) · Kowa Research Institute, Inc. (2) · Takeda (2) · 89bio, Inc. (1) · Abbott (1) · Babu Balagopal (1) · EMS (1) · Excelsior (1)
United States (25) · Canada (14) · Hungary (11) · Czechia (10) · Poland (10) · Bulgaria (9) · France (8) · Netherlands (8) · Spain (8) · Germany (7) · Italy (7) · Russia (6) · Slovakia (6) · Argentina (5) · Denmark (5)
Associate Professor, Clinical Cell Biology and Medicine (2) · Dariush Mozaffarian, MD, DrPH (2) · Michael H Davidson, MD, FACC (2) · Takuya Mori (2) · Angel Brea, MD (1) · Chuen-Den Tseng, M.D., PhD. (1) · Deepak L. Bhatt, MD, MPH (1) · Jean-Claude Tardif, MD (1)
PMID 22087637, PMID 23325450, PMID 25893544, PMID 27206952, PMID 27418543, PMID 27596132, PMID 27939227, PMID 34989797, PMID 40064331, PMID 41211918, PMID 20451686, PMID 20524719, PMID 21683321, PMID 22108152, PMID 22819432, PMID 23312052, PMID 23835245, PMID 23992935, PMID 23998969, PMID 24528690, PMID 25084280, PMID 26044516, PMID 26073397, PMID 26328624, PMID 29583081, PMID 30415628, PMID 30788718, PMID 30898607, PMID 31277790, PMID 31306043, PMID 31439224, PMID 31707829, PMID 33010162, PMID 33148016, PMID 33798466, PMID 34620410, PMID 34706555, PMID 34710343, PMID 35027114, PMID 35261279, PMID 35377160, PMID 35483753, PMID 35762321, PMID 36802845, PMID 37164837, PMID 38035037, PMID 38156550, PMID 39968782, PMID 40081744, PMID 40587053
2023 (4), 2014 (1)